Leiden, The Netherlands, Nov. 10, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) todayannounced that the Company will host a conference call and liveaudio webcast on Monday, November 17, 2014 at 8:00a.m. US Eastern Time (2:00 p.m. Central European Time) toreport its third quarter financial results and provide a corporateupdate. In order to participate in the conference call,please dial 1-877-407-9170 (US Domestictoll-free). International dial-in numbers and an audio webcastcan be accessed under "Events & Presentations" through theInvestors & Media section of the Prosensa corporate websiteat www.prosensa.com. About Prosensa Holding N.V. Prosensa (NASDAQ: RNA) is a biotechnologycompany engaged in the discovery and development of RNA-modulatingtherapeutics for the treatment of genetic disorders. Its primaryfocus is on rare neuromuscular and neurodegenerative disorders witha large unmet medical need, including Duchenne muscular dystrophy(DMD), myotonic dystrophy and Huntington's disease. Prosensa's current portfolio includes sixcompounds for the treatment of DMD, all of which have receivedorphan drug status in the United States and the European Union. Thecompounds use an innovative technique called exon-skipping toprovide a personalized medicine approach to treat differentpopulations of DMD patients. www.prosensa.com About DMD DMD is one of the most prevalent rare geneticdiseases globally affecting up to 1 in 3,500 boys and is invariablyfatal. There is currently no approved disease-modifying therapy forDMD. The progressive muscle-wasting that characterizes this diseaseis caused by inadequate production of dystrophin, a proteinnecessary for muscle function, as a result of mutations in thedystrophin gene. The different mutations, which are mostlydeletions of one or more exons, found in the dystrophin gene resultin distinct sub-populations of DMD patients.
CONTACT: Celia Economides, Senior Director IR & Corporate Communications Phone: +1 917 941 9059 Email: email@example.com